Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00336544
Status:
COMPLETED
Last Update Posted:
2010-02-26
First Post:
2006-06-09
Brief Title:
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
Sponsor:
Advanced Life Sciences Inc
Organization:
Advanced Life Sciences Inc
Study Overview
Official Title:
A Double-Blinded Randomized Parallel Group Multi-Center Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia CAP
Detailed Description:
Lower respiratory tract infections remain one of the leading causes of death worldwide Increasing rates of antibiotic resistance and newer more pervasive pneumonia-causative pathogens contribute to this statistic Currently available macrolide antibiotics for the treatment of community-acquired pneumonia are slowly losing effectiveness resulting in the need to develop newer drugs to fight resistant infections In this study we compare the safety and efficacy of a common macrolide clarithromycin to a new ketolide cethromycin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None